1st QTR PROFITS UP 7% AT ICI

10 May 1992

For the first quarter of 1992, Imperial Chemical Industries made group pretax profit of L 212 million ($376.6 million). Turnover for the period improved slightly, up 1% to L 3.06 billion. Higher sales volume, mainly in the USA and Continental Europe, and favorable exchange movements were said to have been offset by the net effect of divestments and lower local selling prices, mainly in Europe.

"We are pleased to report a 7% increase in our profits as compared with the first quarter of 1991. In bioscience products, pharmaceuticals continued to show good results. Elsewhere there are signs of improvement in the specialty chemicals and materials businesses with paints a strong performer. However, margins continue to be depressed in our industrial chemical operations where customer demand is still weak," said chairman Sir Denys Henderson.

Pharmaceutical turnover for the first quarter was L 386 million, up 19% on the like, year-earlier period. Trading profit grew 39% to L 122 million.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight